Drug & intervention

dapagliflozin 10 MG [Farxiga]

RxCUI 1534397

Clinical trials6

Recruiting0

Related conditions10

Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

6 shown

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney DiseaseNCT05719714 · 2024-01-16

ACTIVE_NOT_RECRUITING

Dapagliflozin in Pulmonary Arterial HypertensionNCT05179356 · 2023-01-01

Dapagliflozin Treatment in Type 2 DiabetesNCT04620590 · 2021-04-20

Combination GRA and SGLT-2i Treatment in Type 1 DiabetesNCT04545411 · 2021-02-22

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEFNCT04739215 · 2021-01-15

Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery DiseaseNCT03398577 · 2018-02-01

Conditions being studied

Diabetes Mellitus, Type 22 Heart Failure With Preserved Ejection Fraction2 Chronic Kidney Diseases1 Chronic Thromboembolic Pulmonary Hypertension1 Coronary Disease With Diabetes Mellitus1 Heart Failure1 Impaired Renal Function1 Kidney Diseases1 Pulmonary Arterial Hypertension1 Type 1 Diabetes1

Research locations

AuroraColorado, United States1 ChicagoIllinois, United States1 CopenhagenDenmark1 La JollaCalifornia, United States1 MadridSpain1 TorontoOntario, Canada1

Leading sponsors

Emerald Clinical Inc.1 Hospital General Universitario Gregorio Marañon1 Mads Ersbøll1 Northwestern University1 Sheba Medical Center1 University of California, San Diego1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.